NCT06081621View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BIOLOGICAL

REGEND001

REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.

BIOLOGICAL

Placebo

Placebo: Sodium chloride injection administrated by bronchoscopy.

Trial Locations (4)

200025

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai

200127

Renji Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai

361021

The Second Affiliated Hospital of Xiamen Medical College, Xiamen

Unknown

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

The Second Affiliated Hospital of Xiamen Medical College

UNKNOWN

lead

Regend Therapeutics

INDUSTRY

NCT06081621 - A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter